New gout drug shows promise in lowering uric acid levels
NCT ID NCT05815901
First seen Apr 12, 2026 · Last updated May 17, 2026 · Updated 9 times
Summary
This phase 3 study tested a new drug called epaminurad against the standard gout medication febuxostat in 612 adults with gout. The goal was to see which drug better lowers uric acid levels below 6 mg/dL over time. Participants took either epaminurad or febuxostat, and researchers measured uric acid levels at multiple visits. This is a disease control study, meaning it aims to manage gout rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inha University Hospital
Incheon, South Korea
Conditions
Explore the condition pages connected to this study.